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Nutritional status and eating behaviors play a significant role in the clinical effects of 
prescription drugs. Foods may alter the effect of drugs by interfering with 
pharmacokinetic and pharmacodynamic mechanisms. In addition, the use of drugs 
that interact with nutrients and affect eating behaviors are especially problematic for 
the elderly, and, in addition to other health problems, frequently leads to 
malnutrition. Despite the large clinical literature on the importance of specific drug-
food interactions, little is known regarding these risks among the elderly. Magee 
Rehabilitation Hospital has a long history of providing rehabilitation and primary 
prevention programs for the elderly and is very interested in the potential role that 
drug-food interactions may play in age related health problems including injury 
secondary to falls. 
 
In June of 1998 Magee Rehabilitation initiated the Medication Safety Program (MSP), 
a three-phase research and demonstration project funded by SmithKline Beecham 
Community Partnership. The goal of this research project was to explore the nature 
and extent of risks, and the degree to which elderly are knowledgeable and 
compliant regarding drug-food risks, in order to develop effective risk-reduction 
interventions. In addition to Magee Rehabilitation and SmithKline Beecham, the MSP 
partners included the Pennsylvania Department of Aging, the Pennsylvania 
Department of Aging’s Pharmaceutical Assistance Contract for the Elderly (PACE) 
Program, First Health Services Corporation, the Pennsylvania State University 
(Departments of Biobehavioral Health and Nutrition), the Philadelphia Corporation for 
Aging, MCP Hahnemann University, HealthGuard, HealthCentral and Sessa & 
Associates.   
 
Phase I of the MSP used historical data to examine the epidemiology of drug-food 
interactions related to fluid and electrolyte balance in the PACE population. Several 
databases containing pharmacy claims, drug attributes, and hospitalization records 
were linked and analyzed retrospectively.  
 
The first study, which examined the association between prescription drug use and 
dehydration, found that 14% of all 1997 hospitalizations of PACE cardholders were 
associated with a diagnosis of dehydration. Older age, male gender, nursing home 
residence, and African-American race were all significantly and independently 
associated with increased risk for dehydration. Dehydration risk increases by 11% to 
36% with each additional potentially dehydrating drug that is taken. 
 
The second study examined differences between blacks and whites for hospitalization 
with hyperkalemia and hypokalemia. About 2% of hospitalized PACE enrollees were 
diagnosed with hyperkalemia, and 6% were diagnosed with hypokalemia. 
Hyperkalemia cases were more likely than controls to have used ACE inhibitors. In 
this study, blacks experienced greater risk of hospitalization with hyperkalemia than 
did whites, and this difference remained even when controlling for ACE inhibitor use.  
However, there was no difference between groups in risk of hypokalemia. 
 
Phase II of the MSP was comprised of two cross-sectional surveys—telephone and 
mail—of PACE enrolled elderly. The surveys were targeted to specific risk groups of 
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elderly who were determined to be at risk for specific adverse effects of drug-food 
interactions. Risk groups included 1) elderly with diabetes; 2) warfarin users; 3) 
antihypertensive users; 4) users of drugs with potential appetite-suppressant 
effects; and 5) a random sample of PACE-enrolled elderly. 
 
Of the 3,254 elderly who were contacted and identified as eligible for the study, 
1,102 completed the telephone interview and of these, 81.7% subsequently 
completed the mail survey. Results on risk indicators for 3 of the 5 risk groups 
(elderly persons using antidiabetics, antihypertensives and anticoagulants) 
unambiguously indicate that there is risk for significant adverse clinical consequences 
due to lack of adequate knowledge of drug-food interactions and other health 
promoting behaviors. 
 
Less than 40% of individuals on anti-diabetic medications reported that they knew 
certain foods could affect how well some medicines work. Only 1 out of 5 knew that 
certain foods could cause problems with the particular medicines they were taking. 
Among elderly antihypertensive users, only about 1 in 4 knew that certain foods 
affect how well some medicines work. Survey results suggest that fewer than 1 in 4 
users of anticoagulants are aware that dietary behaviors and some foods can cause 
significant problems with the physiological effects of their anticoagulant medication.  
Moreover, 3 out of 4 of this group report not receiving recommendations on eating 
behaviors from any of their physicians or pharmacists. Finally, significant numbers of 
elderly users of anticoagulants may be generally lax about medication safety with 
about 12% reporting either taking fewer tablets than prescribed, taking their 
medication less frequently, or else completely stopping taking a prescription.   
 
Contrary to expectations, our findings suggest that PACE participants taking centrally 
active medications with appetite suppressant properties may be at particular risk for 
health problems associated with obesity, rather than appetite and weight loss. More 
than 9 out of 10 elderly using drugs with appetite suppressant effects were not 
advised about the possible effects of their medications on appetite. 
 
Phase I and II of the Medication Safety Program (MSP) have already made a 
significant impact on at least one large-scale health care system in Pennsylvania. 
Based on the results of the first two phases of this research program, PACE has 
agreed to include risk surveillance for drug-nutrition as part of their Retrospective 
Drug Utilization Review and Prospective Drug Utilization Review systems.  Still, the 
full impact of the MSP program will not be realized until the completion of the 
proposed Phase III Intervention Plan.  Thus far, the MSP research findings from 
Phase I and Phase II have mainly the potential to improve the health of the elderly 
by justifying interventions and by raising the consciousness of health care planners 
and providers.  The true large-scale impact of the MSP program will be realized 
through funding and implementation of the planned Phase III risk-reduction 
programs. 
 
For more information contact Lynn McGillin at 215-587-3180. 
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